SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development of $8.24M in Q1 FY2026
Q1 FY2026 research & development was $8.24M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 28.64M USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.64M | — |
Research & Development vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.44B USD | +51.4% | +12.1% | 13.1% | |
| LTM Jun 2026 | $404M USD | +12.5% | +6.5% | 7.6% | |
| LTM Mar 2026 | $234.61M USD | +45.4% | +64.5% | 3080.9% | |
| LTM Mar 2026 | $220.45M USD | +47.2% | +54.5% | 423.6% | |
| LTM Jun 2026 | $177.17M USD | +26.4% | +6.9% | 28.9% | |
| LTM Mar 2026 | CHF 56.48M CHF | +0.9% | +34.9% | 11206.4% | |
| LTM Apr 2026 | $38.43M USD | -26.2% | +3.6% | 13.2% | |
| LTM Mar 2026 | $37.65M USD | +2.6% | +14.1% | 29.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $28.64M USD | — | — | — |
| LTM Mar 2026 | $12.72M USD | -28.5% | -13.9% | 16.0% | |
| Peer median (excluding SGP) | — | +12.5% | +12.1% | 28.9% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.